These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 34236011)
1. Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial. Dong W; Chen M; Niu S; Wang B; Xia L; Wang J; Shen T; Wang Q; Lv J; Liu G; Fan H; Xie Z; Xie F; An Y; Zheng Q; Rao H; Song H; Fang Y Expert Opin Biol Ther; 2022 Feb; 22(2):253-262. PubMed ID: 34236011 [TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects. Zhou R; Yang J; Liu Y; Zhang Q; Lu C; Tang K; Li X; Tang W; Gao E; Wu C; Dou C; Hu W Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787 [TBL] [Abstract][Full Text] [Related]
3. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers. Zhu X; Qian H; Sun J; Wu M; Yu C; Ding Y; Zhang X; Chai K; Li X Cancer Chemother Pharmacol; 2021 Sep; 88(3):465-474. PubMed ID: 34086067 [TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men. Singh I; Patel R; Patel A; Jose V Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073 [TBL] [Abstract][Full Text] [Related]
5. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males. Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects. Liu YN; Huang J; Guo C; Yang S; Ye L; Wu ST; Zhang XF; Yang XY; Han CC; Pei Q; Huang L; He QN; Yang GP Cancer Chemother Pharmacol; 2020 Mar; 85(3):555-562. PubMed ID: 31907645 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin®) in Healthy Chinese Subjects. Xie L; Zhu Y; Liang Z; Zhao Y; Zhou S; Chen J; Zhang H; Ding S; Wang L; Shao F Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):309-317. PubMed ID: 35112328 [TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects. Liu Z; Gao Z; Yang W; Zhang L; Xiao N; Qu D; Su Z; Xu K; Liu G; Wang Y; Ren Q; Yu S; Cheng Y; Zhou Y; Deng Q; Zhao Y; Wang Z; Yang H Expert Opin Drug Metab Toxicol; 2022; 18(7-8):519-527. PubMed ID: 35961948 [TBL] [Abstract][Full Text] [Related]
9. A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin Wu J; Wu G; Xie L; Lv D; Xu C; Zhou H; Wu L; Zhang J; Shentu J Drugs R D; 2023 Jun; 23(2):175-183. PubMed ID: 37247166 [TBL] [Abstract][Full Text] [Related]
10. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022 [TBL] [Abstract][Full Text] [Related]
11. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers. Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267 [TBL] [Abstract][Full Text] [Related]
12. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects. Zhang Q; Sun C; Wu J; Wu J; Zhang X; Liu Y; Dou C; Qin H; Zhang Q; Zhou R; Hu W Expert Opin Biol Ther; 2023; 23(8):727-735. PubMed ID: 36880118 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study. Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358 [TBL] [Abstract][Full Text] [Related]
15. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects. Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study. Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670 [TBL] [Abstract][Full Text] [Related]
17. A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects . Zhang H; Zhu X; Wei H; Li C; Chen H; Li X; Wu M; Liu J; Chen G; Zhou H; Zheng S; Ding Y Int J Clin Pharmacol Ther; 2019 Mar; 57(3):167-174. PubMed ID: 30663977 [TBL] [Abstract][Full Text] [Related]
18. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers. Sinn A; García-Alvarado F; Gonzalez V; Huerga C; Bullo F Br J Clin Pharmacol; 2022 Mar; 88(3):1063-1073. PubMed ID: 34374114 [TBL] [Abstract][Full Text] [Related]
19. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx Yao F; Wang C; Ding J; Zhang Q; Zheng L; Zhang Q; Yang T; Zhang X; Shan Y; Hou S; Wang H; Zhou R; Hu W Drug Des Devel Ther; 2024; 18():3891-3901. PubMed ID: 39224901 [TBL] [Abstract][Full Text] [Related]
20. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects. Hanes V; Chow V; Pan Z; Markus R Cancer Chemother Pharmacol; 2018 Nov; 82(5):899-905. PubMed ID: 30269275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]